Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
AstraZeneca
McKesson
Covington
Citi
Harvard Business School
Baxter
Express Scripts
Merck
Cantor Fitzgerald

Generated: February 19, 2018

DrugPatentWatch Database Preview

XOPENEX HFA Drug Profile

« Back to Dashboard

Which patents cover Xopenex Hfa, and when can generic versions of Xopenex Hfa launch?

Xopenex Hfa is a drug marketed by Sunovion and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-six patent family members in eighteen countries.

The generic ingredient in XOPENEX HFA is levalbuterol tartrate. There are nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the levalbuterol tartrate profile page.
Summary for XOPENEX HFA
International Patents:36
US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: 5
Clinical Trials: 6
Drug Prices:see details
DailyMed Link:XOPENEX HFA at DailyMed
Drug patent expirations by year for XOPENEX HFA
Pharmacology for XOPENEX HFA

US Patents and Regulatory Information for XOPENEX HFA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for XOPENEX HFA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 ➤ Sign Up ➤ Sign Up
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 ➤ Sign Up ➤ Sign Up
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 ➤ Sign Up ➤ Sign Up
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 ➤ Sign Up ➤ Sign Up
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 ➤ Sign Up ➤ Sign Up
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 ➤ Sign Up ➤ Sign Up
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 ➤ Sign Up ➤ Sign Up
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 ➤ Sign Up ➤ Sign Up
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 ➤ Sign Up ➤ Sign Up
Sunovion XOPENEX HFA levalbuterol tartrate AEROSOL, METERED;INHALATION 021730-001 Mar 11, 2005 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for XOPENEX HFA

Country Document Number Estimated Expiration
New Zealand 541168 ➤ Sign Up
Spain 2626648 ➤ Sign Up
Germany 60304900 ➤ Sign Up
Mexico PA05006087 ➤ Sign Up
Portugal 1572622 ➤ Sign Up
Japan 4570960 ➤ Sign Up
Slovenia 1671942 ➤ Sign Up
Denmark 1671942 ➤ Sign Up
Australia 2003295695 ➤ Sign Up
Germany 60336089 ➤ Sign Up
Country Document Number Estimated Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
Johnson and Johnson
Chubb
Boehringer Ingelheim
Merck
Teva
Cipla
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot